Literature DB >> 22313727

The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer.

Mario Richterstetter1, Bernd Wullich, Kerstin Amann, Lothar Haeberle, Dirk Gerhard Engehausen, Peter Juergen Goebell, Frens Steffen Krause.   

Abstract

UNLABELLED: Transurethral resection of bladder tumour (TURBT) is the 'gold standard' in the diagnosis and therapy of non-muscle-invasive bladder cancer. To improve the quality of this technique an additional TUR (after 4-6 weeks) or a simultaneous photodynamic diagnosis is often offered. The present study shows different variables that influence, to a greater or lesser extent, the accuracy of the TUR diagnosis and the success of the operation. This is very important for the further management of bladder cancer, be it in tumour follow-up or in preparation for more invasive therapies.
OBJECTIVE: To analyse the impact of a standardised extended transurethral resection of bladder tumour (TURBT) protocol on the determination of the residual tumour status at initial TURBT session and recurrence rate in the primary resection area. Despite, the fact that there is a clear consensus on the aims of TURBT, there is little agreement on how to perform TURBT to achieve that goal. PATIENTS AND METHODS: We retrospectively evaluated 221 consecutive patients, who underwent 305 TURBT sessions for bladder cancer, including patients with recurrent tumours. All the TURBTs were extended by taking additional deep and marginal specimens, according to a standardised protocol. Clinical and histopathological data were retrieved from the patients' records.
RESULTS: Across all tumour stages, residual tumour (pR1) was found in 38% of the additionally taken specimens. There was a significant association of pR1 status with tumour stage, grade, and size. Also in the group of non-muscle-invading tumours, the rate of R1 resection was rather high at 22%. There was no association with focality and the training status of the surgeon. At follow-up, of all the patients with a unifocal primary tumour there was recurrence in the same area as the primary in 5.1%.
CONCLUSIONS: Extended TURBT provides detailed information about the horizontal and vertical extent of the bladder tumour. The implementation of standardised TURBT procedures, such as our protocol of an extended TURBT, is greatly needed to improve local tumour control. Whether a diagnostic re-TUR may be restricted to those cases with positive margins or ground specimens remains to be studied.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2012        PMID: 22313727     DOI: 10.1111/j.1464-410X.2011.10904.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  18 in total

Review 1.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

2.  Transurethral En Bloc Resection of Bladder Tumor Using an Endoscopic Submucosal Dissection Technique: Preliminary Results in an Animal Model.

Authors:  Shuichi Morizane; Takehiro Sejima; Hideto Iwamoto; Toshihiko Masago; Masashi Honda; Yuichiro Ikebuchi; Kazuya Matsumoto; Masaru Ueki; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2016-06-29       Impact factor: 1.641

Review 3.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

4.  [T1 bladder cancer: role of documentation for bladder tumor findings and targeted second resection].

Authors:  D A Lazica; S Böttcher; S Degener; F-C von Rundstedt; A S Brandt; S Störkel; S Roth
Journal:  Urologe A       Date:  2013-08       Impact factor: 0.639

5.  Initial experience of combined use of photodynamic diagnosis and narrow band imaging for detection of flat urothelial lesion.

Authors:  Yoshio Naya; Masakastu Oishi; Yasunori Yamada; Takashi Ueda; Atsuko Fujihara; Hiroyuki Nakanishi; Yasuyuki Naito; Terukazu Nakamura; Fumiya Hongo; Kazumi Kamoi; Koji Okihara; Tsuneharu Miki
Journal:  Int J Clin Oncol       Date:  2014-09-18       Impact factor: 3.402

6.  The value of extensive transurethral resection in the diagnosis and treatment of nonmuscle invasive bladder cancer with respect to recurrence at the first follow-up cystoscopy.

Authors:  Yunkai Qie; Hailong Hu; Dawei Tian; Yu Zhang; Linguo Xie; Yong Xu; Changli Wu
Journal:  Onco Targets Ther       Date:  2016-04-05       Impact factor: 4.147

Review 7.  How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

Authors:  Seok Joong Yun; Seon-Kyu Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-06-10

Review 8.  An uncommon manifestation of paraneoplastic cerebellar degeneration in a patient with high grade urothelial, carcinoma with squamous differentiation: A case report and literature review.

Authors:  Yaofeng Zhu; Shouzhen Chen; Songyu Chen; Jing Song; Fan Chen; Hu Guo; Zhenhua Shang; Yong Wang; Changkuo Zhou; Benkang Shi
Journal:  BMC Cancer       Date:  2016-05-21       Impact factor: 4.430

9.  Transurethral Use of Evicel(®) Fibrin Sealant.

Authors:  Jonathan L Masel
Journal:  Urol Case Rep       Date:  2015-11-27

10.  Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.

Authors:  Piotr Zapała; Bartosz Dybowski; Sławomir Poletajew; Łukasz Białek; Andrzej Niewczas; Piotr Radziszewski
Journal:  World J Surg Oncol       Date:  2018-01-15       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.